openPR Logo
Press release

Friedreich’s Ataxia (FRDA) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top Key Players are Reata Pharmaceuticals, Inc., AbbVie, Takeda

06-17-2019 02:42 PM CET | Health & Medicine

Press release from: Pharma Proff

Friedreich’s Ataxia (FRDA) Therapeutics Pipeline to Witness

Friedreich’s ataxia (FRDA) is an inherited autosomal recessive genetic condition that progressively damages the nervous system, with a typical age of onset between 10 years and 15 years. The risk factors associated with FRDA are diabetes mellitus and heart diseases, including cardiomyopathy and cardiac arrhythmias. FRDA occurs due to mutation in the frataxin (FXN) gene, which is inherited from parents, leading to the presence of mutations in both copies of FXN gene. Initial symptoms of FRDA include frequent falling, difficulty in walking owing to impairment in the coordination ability voluntary movements (ataxia), and unsteady posture. People with FRDA also develop characteristic foot deformities, unbalanced sideways or lateral curvature of the spine (scoliosis), degeneration in the sensory nerve fibers at dorsal root ganglia, impaired swallowing, and slurred speech (dysarthria).

Download the sample report at: https://www.pharmaproff.com/request-sample/1241

FRDA is usually diagnosed through genetic testing to search the levels of FXN in spinal cord and brain. Medications and therapies are available only to treat the symptoms associated with FRDA. For instance, angiotensin-converting enzyme (ACE) inhibitors, beta blockers, and diuretics are used to control cardiac abnormalities that occurs due to FRDA.

According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered by the oral route. It has been observed that the oral route of medication is convenient, improved the patient’s compliance, less risk of systemic infections, and inexpensive in nature. Administration of therapeutics for FRDA through oral route has shown promising results in the clinical studies.

Get the detailed analysis at: https://www.pharmaproff.com/report/frda-therapeutics-pipeline-analysis

Companies that are involved in developing therapeutics for FRDA have shown positive clinical results in the various phases of drug development. For instance, in June 2017, Reata Pharmaceuticals Inc. announced the positive data of phase II clinical study of omaveloxolone for the treatment of FRDA. The drug candidate induced nuclear factor erythroid 2–related factor 2 (Nrf2) which is suppressed in FRDA patients; and improved mitochondrial and neurological function.

In November 2017, JOTROL, a unique formulation of trans-resveratrol developed by Jupiter Orphan Therapeutics Inc. to treat patients with FRDA, received Orphan Drug Designation by the U.S. Food and Drug Administration (USFDA). The Orphan Drug Designation may help to facilitate drug development of JOTROL for the treatment of FRDA that accelerates the process of development.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1241

AbbVie Inc., Reata Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, and Jupiter Orphan Therapeutics Inc. are some of the key companies involved in the development of FRDA therapeutics.

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of FRDA. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the FRDA therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to FRDA.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Friedreich’s Ataxia (FRDA) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top Key Players are Reata Pharmaceuticals, Inc., AbbVie, Takeda here

News-ID: 1777888 • Views: 703

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for FRDA

Friedreich’s Ataxia Therapeutics Pipeline Analysis - Cardero Therapeutics, Inc …
According to the research findings, most of the drug candidates in Friedreich's ataxia therapeutics pipeline are being developed to be administered by oral route. Browse report sample at: https://www.psmarketresearch.com/market-analysis/frda-therapeutics-pipeline-analysis/report-sample *Various Grants from Friedreich's Ataxia Research Alliance (FARA) Catabasis Pharmaceuticals, Inc. received Kyle Bryant Translational Research award from the FARA for the evaluation of their drug candidate, which is being developed for the treatment of Friedreich’s ataxia. *Drugs are being developed using natural sources in
Friedreich’s Ataxia Therapeutics Key Players Analysis - Cardero Therapeutics, …
The study analyzed that the Friedreich's ataxia therapeutics pipeline comprises approximately 17 drug candidates in different stages of development. Friedreich’s ataxia is an autosomal recessive inherited genetic disorder that progressively damages the nervous system. Its initial symptoms include ataxia, impaired muscle coordination and impaired speech. This results in development of dysarthria, scoliosis, heart diseases and diabetes, but does not affect cognitive function. Browse report sample at: https://www.psmarketresearch.com/market-analysis/frda-therapeutics-pipeline-analysis/report-sample Catabasis Pharmaceuticals, Inc. received Kyle
Friedreich's Ataxia Therapeutics - Pipeline Analysis, Clinical Trials & Results, …
the Friedreich's ataxia therapeutics pipeline comprises approximately 17 drug candidates in different stages of development. Friedreich’s ataxia is an autosomal recessive inherited genetic disorder that progressively damages the nervous system. Its initial symptoms include ataxia, impaired muscle coordination and impaired speech. This results in development of dysarthria, scoliosis, heart diseases and diabetes, but does not affect cognitive function. According to the research findings, most of the drug candidates in Friedreich's ataxia